Is Another Heparin Crisis Looming? Congress Raises Alarm, Demands US FDA Briefing
Executive Summary
The FDA must explain how it will prevent heparin adulteration as a virus kills pigs in China again.
You may also be interested in...
FDA CDER Compliance Office Answered Pandemic With Fewer Inspections, Greater Discretion
Fewer inspections but more warning letters, import alerts and drug-shortage discretions were seen as office sought to ameliorate COVID-19 impacts.
The Quality Lowdown: Import Alert Update
Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.
China Heparin Quality Under Pressure Again, Congress Warns FDA
US House committee requests FDA commissioner to provide a contingency response plan should pressures on China's heparin supply chain trigger more of the economically motivated adulteration that killed scores of US patients in 2008.